Perinatal asphyxia is a common cause of neurologic morbidity in neonates who are born at term. Asphyxiated neonates are frequently treated with analgesic medications, including opioids, for pain and discomfort associated with their care. On the basis of previous laboratory studies suggesting that opioids may have neuroprotective effects, we conducted a retrospective review of medical records of 52 neonates who were admitted to our neonatal intensive care unit between 1995 and 2002 and had undergone magnetic resonance imaging (MRI) of the brain. Our review revealed that 33% of neonates received morphine or fentanyl. The neonates who received opioids also had experienced hypoxic/ischemic insults of greater magnitude as suggested by higher plasma lactate levels and lower 5-min Apgar scores. It is interesting that the MRI studies of neonates who were treated with opioids during the first week of life demonstrated significantly less brain injury in all regions studied. More important, follow-up studies of a subgroup of opioid-treated neonates whose MRI scans were obtained in the second postnatal week had better long-term neurologic outcomes. Our results suggest that the use of opioids in the first week of life after perinatal asphyxia have no significant long-term detrimental effects and may increase the brain's resistance to hypoxicischemic insults. Immediately after birth, asphyxiated neonates who are admitted to the neonatal intensive care unit (NICU) experience repetitive invasive and noninvasive procedures, such as endotracheal intubation, arterial line placement, i.v. catheterization, intramuscular injections, and endotracheal suctioning. Although necessary steps in the care of these neonates, such procedures result in pain and prolonged stress during a critical time associated with rapid brain growth and development (1). In addition to causing abnormalities in respiration, heart rate, and blood pressure (2), neonatal pain may alter neuronal and synaptic organization (3) and potentiate the effects of hypoxia (4). Animal studies show that exposure to untreated repetitive pain and stress results in prolonged firing of C-fibers, causing glutamate-induced N-methyl-D-aspartate (NMDA) receptor activation (5). This may augment hypoxia-induced glutamate release, an important mechanism that contributes to neuronal injury or death.
Immediately after birth, asphyxiated neonates who are admitted to the neonatal intensive care unit (NICU) experience repetitive invasive and noninvasive procedures, such as endotracheal intubation, arterial line placement, i.v. catheterization, intramuscular injections, and endotracheal suctioning. Although necessary steps in the care of these neonates, such procedures result in pain and prolonged stress during a critical time associated with rapid brain growth and development (1) . In addition to causing abnormalities in respiration, heart rate, and blood pressure (2) , neonatal pain may alter neuronal and synaptic organization (3) and potentiate the effects of hypoxia (4) . Animal studies show that exposure to untreated repetitive pain and stress results in prolonged firing of C-fibers, causing glutamate-induced N-methyl-D-aspartate (NMDA) receptor activation (5) . This may augment hypoxia-induced glutamate release, an important mechanism that contributes to neuronal injury or death.
Opioid analgesics such as morphine and fentanyl are administered to critically ill neonates in an effort to reduce pain and stress (6) . The antinociceptive effects of these medications are mediated through a combined presynaptic and postsynaptic hyperpolarization, leading to reductions in the release of and sensitivity to endogenous mediators such as glutamate (7, 8) . These data suggest that opioids might confer neuroprotection by decreasing excitotoxicity through reductions in glutamate release, leading to greater overall reductions in neurologic damage. Cell culture studies indicate that both endogenous and exogenous opioids can protect cortical neurons from hypoxiainduced cell death (9, 10) and induce ischemic tolerance in cerebellar Purkinje cells that are subjected to ischemiareperfusion conditions (11) . Opioid receptor agonists were shown to increase tissue preservation and survival time of organs before their use in transplantation surgery (12) and increase survival time during severe hypoxia in intact animals (13, 14) . In ventilated preterm neonates, clinical trials of lowdose morphine or fentanyl infusion have demonstrated conflicting results. Although several pilot studies (15, 16) as well as a large randomized trial supported the neuroprotective role of opioids (17) , a recently published study in ventilated preterm neonates of 24 -32 wk gestation demonstrated that preemptive low-dose morphine infusion did not reduce the incidence of neonatal death, intraventricular hemorrhage, or periventricular leukomalacia (18) . Although these results are important, none of these studies included term infants and all excluded infants with severe perinatal asphyxia. In addition, these studies did not examine long-term outcome but focused on acute neurologic status at 36 wk after conception (16) or at 28 -35 postnatal days (17, 18) .
To evaluate the effects of opioid analgesia on neuroimaging and clinical outcomes, we conducted a retrospective review of medical records of neonates who were admitted to our NICU and had undergone magnetic resonance imaging (MRI) of the brain for perinatal asphyxia. We tested the hypothesis that opioid analgesics that are administered during the first week of life can alter the severity of acute and long-term neurologic injury in full-term neonates who are exposed to perinatal asphyxia. The first postnatal week was chosen on the basis of animal studies on brain energy metabolism that characterized the term human brain's first postnatal week to be particularly vulnerable to the effects of hypoxic energy failure (19) . This period of heightened vulnerability corresponded with marked declines in phosphocreatine and nucleoside triphosphates in response to hypoxemia (19) as well as developmentally programmed increases in the expression of specific excitatory amino acid receptors (20) . In addition, neonates are subjected to the highest number of painful procedures during the first week of life, with painful procedures occurring 6 -14 times per day (21, 22) . Our aim was to compare clinical, neuroimaging, and long-term outcomes in opioid-treated versus nontreated neonates to determine whether opioids play a role in decreasing acute and long-term neurologic injury.
METHODS
Patient data. Medical, radiologic, and research records of newborns with brain injury were reviewed. Inclusion criteria were MRI scan in the first month of life and at least one of the following criteria for perinatal asphyxia: 1) 5-min Apgar score of Յ5, 2) umbilical cord arterial pH Յ7.10, 3) umbilical cord base excess ՆϪ10, and 4) clinical postasphyxial syndrome (encephalopathy, seizure, intraventricular hemorrhage). Exclusion criteria were 1) proven congenital infection or metabolic disease or 2) CNS or other major malformations. This study was reviewed and approved by the Loma Linda University Institutional Review Board.
Review of the medical records was performed and infant physical characteristics such as estimated gestational age, birth weight, and sex were recorded. To define the infant's condition immediately after birth, we also recorded the neonate's initial chemical (blood gas, electrolytes) and hematologic data as well as the results of the first neurologic examination. We also examined maternal and labor and delivery histories to determine the presence or absence of risk factors that are known to affect neurologic outcome. These factors include maternal and fetal conditions such as inflammation or infection (23) , alcohol or illicit drug abuse (24) , and intrapartum events that result in prolonged and catastrophic asphyxia (e.g. cord compression) (25) .
Use of opioid analgesics. Individual patient medication administration records, nursing forms, physician's order sheets, and the institution's pharmacy records were reviewed for documentation of administration of opioid analgesics. The MRI scans of neonates who received morphine, fentanyl, or meperidine in the first week of life were compared with those who did not receive any of these opioids. Treated neonates were found to have received one of the following: 1) morphine 0.1 mg/kg i.v. every 2-6 h as needed or fentanyl 2-5 To quantify the extent and the severity of brain damage in opioid-treated and nontreated infants, we used an MRI scoring system that assigns a numerical score to the severity of injury in the basal ganglia and watershed zones, regions that are found on MRI to be particularly vulnerable to hypoxic-ischemic injury in the newborn (26) . MRI scans of the identified neonates were scored by an experienced neuroradiologist (N.W.) who was blinded to clinical information and opioid utilization. Scoring was based on a previously validated scoring system for asphyxiated neonates developed by Barkovich et al. (26) and described in Table 1 . Briefly, each MR scan was scored twice by the same radiologist, with scoring separated in time by Ͼ1 mo. The first and second sets of scores were compared, and intraobserver variability was calculated. The statistic was 0.85, showing high consistency of scoring and low intraobserver variability. This MRI scoring system was previously shown to discriminate between good and poor neuromotor and cognitive outcomes at 3 and 12 mo in asphyxiated neonates (26) .
MRI was performed using a standard circularly polarized head coil in a conventional 1.5T scanner (Vision; Siemens Medical Solutions, Erlangen, Germany). To assess severity of injury in the basal ganglia and watershedcortical regions, we used two sequences: 1) a sagittal T1-weighted spin echo sequence [repetition time (TR)/echo delay time (TE) ϭ 550/22 ms, 4 acquisitions, 5 mm thick], and 2) an axial triple spin echo sequence (TR/TE1/TE2/ TE3 ϭ 3000/22/60/120 ms, 1 acquisition, 5 mm thick). The proton density weighted image (first echo of the triple spin echo sequence; TR/TE ϭ 3000/22 ms) and the T2-weighted image (third echo of triple spin echo sequence; TR/TE ϭ 3000/120) along with the T1 weighted images were evaluated and a basal ganglia (BG) score, a watershed (W) score, and a combined basal ganglia/watershed (BG/W) score were assigned for each type of image.
We first compared the MRI scores of all opioid-treated (n ϭ 17) and nontreated neonates (n ϭ 35) who met study criteria (total n ϭ 52) to demonstrate the early effects of opioid analgesia on brain injury. Subsequently, we compared MRI, Pediatric Cerebral Performance Category Scale (PCPCS), and neuromotor scores (see "Long-term neurologic outcome scores" below) in a subgroup of infants whose MRI scans were performed after day 7 of life (n ϭ 24; 12 in the opioid group and 12 in nonopioid group) on the basis of previous studies that demonstrated that the appearance of the asphyxiated infant's brain evolves during the first 17 d of life (26) . This analysis allowed us to assess the long-term effects of opioid treatment on infants with better defined neuroimaging evidence of brain injury. Long-term neurologic outcome scores. Neurologic outcomes were measured at discharge and subsequent visits using the PCPCS, a six-point outcome scoring system modified from the Glasgow Outcome Scale score (27) . The PCPCS was obtained by an experienced pediatric neurologist (S.A.) who was blinded to MRI or opioid information. This tool quantifies the overall functional and cognitive impairment of neonates and children and has been validated in 1469 pediatric patients after acute CNS injuries (28) . It was also shown to correlate with other measures of psychological outcome (29) . The score includes the following outcomes: 1 for normal, can perform all ageappropriate activities; 2 for mild disability, conscious, alert, and able to interact in most age-appropriate activities and may have a mild neurologic deficit; 3 for moderate disability, conscious, sufficient cerebral function for age-appropriate activities of daily life, but has significant cognitive impairment; 4 for severe disability, conscious, dependent on others for daily support because of impaired brain function; 5 for persistent vegetative state; and 6 for death. Long-term neurologic outcome was also determined using a validated neuromotor scoring system (30) 
Statistics. Continuous data (demographic, chemical, and hematologic data) were analyzed using an independent sample t test and reported as the mean and SEM. Ordinal data (MRI, PCPCS, and neuromotor scores) were analyzed using a nonparametric Mann-Whitney test. The statistic was used to assess intrarater variability agreement for MRI assessments. All statistical analyses were performed using SPSS Statistics for Windows Version 10 (Chicago, IL). Differences were considered significant at p Յ 0.05.
RESULTS

Subjects.
From 1995 to 2002, we reviewed the records of 60 neonates who were admitted to the NICU and also underwent MRI. Eight neonates were excluded: two for CNS anomalies such as rolandic polymicroglia and microcephaly, one for congenital herpes infection, one for appearance of prematurity on examination, one for a poor-quality MRI scan, one for large parenchymal hemorrhage, one for vein of Galen aneurysm, and one for absence of documented hypoxic-ischemic events or sequelae (normal arterial blood gases, normal EEG, etc.). Table  2 summarizes the demographic characteristics of neonates who met the study criteria. The majority of the neonates in both groups were born at outside hospitals and were transferred to Loma Linda NICU at 1.5 Ϯ 0.5 d after birth. Table 3 summarizes the neonates' documented physiologic and neurologic status during labor and delivery and immediately after birth, as well as perinatal risk factors. Neonates in the opioid-treated group had more documented episodes or markers of asphyxial insult such as meconium staining, fetal bradycardia or abnormal heart rate, or multisystem involvement. The majority of neonates in both groups had one or more abnormal neurologic signs consistent with perinatal hypoxic/ ischemic injury.
Opioid analgesics and MRI score. Table 4 describes the demographic and clinical characteristics of all neonates who met study criteria and did (n ϭ 17, 33%) or did not (n ϭ 35, 67%) receive opioid analgesia in the first week of life. The rationale for the clinician's choice to treat or not to treat with opioid analgesia was not well documented in the medical record and was most likely related to the treating clinician's attitudes about neonatal pain and pain therapy (31) . It is interesting that the prescription of opioid analgesia seemed to be related to the severity of the infant's illness. Neonates who received opioids had significantly lower 5-min Apgar score (p Ͻ 0.03), lower pH (p Ͻ 0.046), higher PCO 2 (p Ͻ 0.048), higher Hb (p Ͻ 0.036), and higher serum lactate levels (p Ͻ (Table 4) . Opioid analgesics and long-term outcome. On the basis of information that the appearance of the injured neonatal brain changes significantly during the first 17 d of life and that correlation with long-term outcome was better in patients whose MRI examinations were performed after the first week of life (26), we evaluated the MRI of a subgroup of opioidtreated (n ϭ 12) and nontreated infants (n ϭ 12) whose brains were scanned at or after postnatal day 7 and compared their PCPCS and neuromotor scores. Although opioid-treated infants had significantly lower birth weight and higher lactate levels, all other demographic and clinical laboratory data characteristics were similar between the two groups (Table 5) . When MRI scores were compared, opioid-treated infants had significantly lower scores than nontreated infants (Table 6) . More important, opioid-treated infants whose MRIs were performed at postnatal day 7 and above (n ϭ 6) have better long-term neurologic scores (PCPCS and neuromotor scores) than nontreated infants (n ϭ 9; p Ͻ 0.03). In this subgroup, opioid-treated neonates had their MRI at age 12 Ϯ 1 d, whereas nontreated infants had their MRI at 11 Ϯ 1 d (NS); follow-up evaluations were performed at 13 Ϯ 7 mo for opioid-treated infants and 19 Ϯ 10 mo for nontreated infants (NS). Analysis of patients who were not available for long-term neurologic evaluation revealed six opioid-treated and three non-opioidtreated infants. Those who were lost to long-term neurologic evaluation shared similar clinical and laboratory characteristics with those who were available for follow-up, although treated neonates tend to have better MRI scores than nontreated neonates (BG scores: 0 Ϯ 0 versus 0.33 Ϯ 0.33; p ϭ 0.157).
DISCUSSION
Opioid receptors are widely distributed in the CNS with functions that include pain modulation, cardiorespiratory control, and neuronal activity (32) . Opioids are inhibitory neurotransmitters and are known to attenuate neuronal excitability by stimulating potassium ATP channels, leading to hyperpolarization (42) . Cell culture studies indicate that endogenous opioids are released during hypoxia (35) and that both endogenous and exogenous opioids can protect cortical neurons from hypoxia-induced cell death (9, 10) . Because hypoxia and untreated pain lead to the release of excitatory neurotransmitters such as glutamate (5, 36, 37) , efforts to relieve pain may also attenuate neuronal excitotoxicity and cell injury or death.
Our results suggest that the use of opioids in the first week of life after perinatal asphyxia may have beneficial effects and may increase hypoxic-ischemic tolerance. Our study supports earlier pilot studies (15, 16) as well as the large randomized study by Simons et al. (17) that showed that preemptive morphine infusion decreased neurologic injury by significantly decreasing the incidence of periventricular and intraventricular hemorrhage in preterm neonates as diagnosed by cranial ultrasound. Our findings included neuroimaging and long-term follow-up data that showed more favorable MRI and long-term neurologic outcomes scores in neonates whose MRI examinations were performed after postnatal day 7. Timing of MRI examination may be relevant because of previous observations that tissue changes in the injured brain are more advanced and more easily detected during the second week compared with the first week, resulting in better correlations between longterm outcome and acute structural abnormalities as seen with MRI (26, 38) .
Despite the potential benefit of opioids on asphyxiated term neonates as indicated in this study, caution must be exercised in the use of this class of medications. Available literature suggests that the routine use of opioid analgesics can be complicated by problems such as tolerance, withdrawal, and ventilator dependence (39) . Very few studies have examined the long-term effects of exposure to opioids in the neonatal period. In addition, previous reports indicate that endogenous opioids can suppress DNA synthesis in vivo in immature cerebellar and glial cells (40) , whereas exogenous opioids can exacerbate neurotoxicity in animal models of cerebral ischemia (41) . More important, a recent large, randomized trial by Anand et al. (18) in preterm neonates suggested that although morphine infusion decreased clinical signs of pain, it did not improve neurologic outcome at 28 postnatal days. Inconsistencies in the literature regarding the effects of opioids highlight the possibility that multiple factors are involved and that opioids can be beneficial in certain circumstances but not in others. The challenge lies in determining the nature of these circumstances and the mechanisms involved. Caution therefore must be used in the generalization of findings. Furthermore, although neonates in our opioid-treated group had significantly higher lactate levels and lower pH, higher PCO 2 , and higher base deficits, a selection bias still may have occurred whereby encephalopathic neonates who received opioids were those who were more responsive or had less brain injury at the time of birth compared with those who did not receive opioids. Caution is additionally warranted regarding interpretation of these findings because of important study limitations, such as a small sample size, a retrospective study design, a reduced number of infants available for long-term follow-up, and possible selection bias.
Possible mechanism of neuronal opioid effect. The precise role of morphine and other opioids when used to treat neonatal pain is complex and requires further study. Morphine mimics the cardioprotective effect of ischemic preconditioning, acting through a ␦-opioid receptor-mediated mechanism (42) . A similar mechanism operating in the brain might explain the findings in the current study. Both adenosine and opioids inhibit Ca 2ϩ -dependent neurotransmitter release, and both seem to trigger preconditioning. In some animal studies, evidence suggests that there may be cross-talk between adenosine and opioid-receptor-mediated neuroprotection (43) (44) (45) . In the CNS, adenosine and opioid receptors are physically coupled (46) . Morphine is known to elevate adenosine levels via inhibition of adenosine kinase, resulting in locally increased adenosine concentration (46) . Although morphine might function in part by increasing the levels of neuroprotective adenosine, the metabolic breakdown of adenosine by xanthine oxidase ultimately to urate generates hydrogen peroxide. Alternatively, if intracellular Ca 2ϩ levels remain low as a result of opioidmediated hyperpolarization, then calcium-dependent xanthine oxidase remains inactive and adenosine catabolism is mediated by xanthine dehydrogenase without the generation of hydrogen peroxide and other reactive oxygen species (47) . In addition, low intracellular calcium levels prevent the activation of calcium-dependent destructive proteases, endonucleases, and lipases (48, 49) , further decreasing neurologic damage.
CONCLUSIONS
Our results suggest that the use of opioids in the first week of life after perinatal asphyxia have no significant long-term detrimental effects and may increase the brain's resistance to hypoxic-ischemic insults. However, because of potential complications and neurotoxic effects, additional studies are manditory. Future prospective randomized trials should allow us to examine these opioid pathways to determine whether there is truly an immediate neuroprotective effect on hypoxic-ischemic brain injury and whether these agents can play a role in improving long-term outcome. 
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